World Health Organization Raises Alert Over Acute Lack of Weight-Loss Medications
Under one in 10 individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the global health agency as it issues its first advice on the therapies.
Given more than one billion individuals worldwide now living with obesity, it is calling for increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant obstacles to broad access to the jabs that can aid individuals in losing considerable body mass, explains the organization.
GLP-1 Therapy Scarcity
Despite the current most favorable case, the production of GLP-1 therapies would only suffice for about 100 million people – under 10% of the global need, as stated by the WHO.
The advice urges nations and manufacturers to increase access, by measures like voluntary licensing.
Exclusive production rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.
How Weight-Loss Injections Function
These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so people eat less.
Individuals typically begin shedding pounds after several weeks of beginning the weekly injections.
Evidence points to people may regain a significant portion after a year of discontinuing the drug, as their usual hunger return.
To be carrying excess weight raises your likelihood for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
